NEW YORK (TheStreet) -- Gilead Sciences (GILD) - Get Gilead Sciences Inc. Report stock is advancing by 1% to $109.72 in early afternoon trading on Tuesday, ahead of the release of the company's 2015 third quarter financial results after the market close today.
Analysts are expecting the company to post a year over year rise in both earnings and revenue for the most recent quarter.
Gilead has been forecast to report earnings of $2.87 per share on revenue of $7.82 billion by analysts surveyed by Thomson Reuters.
Last year, the company reported earnings of $1.84 per share on revenue of $6.04 billion for the 2014 third quarter.
Gilead is a research-based biopharmaceutical company based in Foster City, CA.
Insight from TheStreet's Research Team
Bret Jensen commented on Gilead in a recent post on RealMoneyPro.com. Here is a snippet of what Jensen had to say about the stock:
The biotech sector has come under considerable pressure over the past three months and dipped a toe into official bear market territory earlier this month, but I believe the sector has bottomed and should be buoyed by good earnings from Gilead Sciences, Amgen (AMGN) and Celgene (CELG) over the next week.
Want more information like this from Bret Jensen and 40 more of Wall Street's sharpest minds BEFORE your stock moves?Learn more about RealMoneyPro.com now.
Separately, TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:
We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
You can view the full analysis from the report here: GILD